Brief: NGM Bio Presents Preliminary Data From Phase 1 Monotherapy Dose Escalation Trial Of Ngm707

NGM Biopharmaceuticals

07/12/2022 23:47

Dec 7 (Reuters) - NGM Biopharmaceuticals Inc  NGM.O :
    * NGM BIO PRESENTS PRELIMINARY DATA FROM PHASE 1 MONOTHERAPY
DOSE
ESCALATION TRIAL OF NGM707 IN PATIENTS WITH ADVANCED OR
METASTATIC SOLID TUMORS AT 2022 ESMO-IO ANNUAL MEETING
    * NGM BIOPHARMACEUTICALS- NGM707 GENERALLY WELL TOLERATED TO
HIGHEST DOSE EVALUATED (1800 MG) IN MONOTHERAPY ESCALATION;
MAXIMUM TOLERATED DOSE WAS NOT REACHED
    * NGM BIOPHARMACEUTICALS- EARLY SIGNALS OF ANTI-TUMOR
ACTIVITY
DEMONSTRATED ACROSS MULTIPLE TUMOR TYPES. OF 24
RESPONSE-EVALUABLE PATIENTS AS OF NOV 23

Source text for Eikon:  ID:nGNX11j6W3 
Further company coverage:  NGM.O 
 ((reuters.briefs@thomsonreuters.com;))